Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platelet surface receptors and adhesive proteins are a diverse group of membrane-bound molecules essential for hemostasis and the pathogenesis of arterial thrombosis (Gremmel et al., 2016, Arterioscler Thromb Vasc Biol). This category includes the integrin alpha-IIb/beta-3 (GPIIb/IIIa), which serves as the final common pathway for platelet aggregation by binding fibrinogen, and the Glycoprotein Ib-IX-V complex, which mediates initial adhesion to von Willebrand factor (Li et al., 2010, J Biol Chem). Additionally, G protein-coupled receptors such as P2Y12 and Protease-activated receptor-1 (PAR-1) play critical roles in amplifying platelet activation in response to ADP and thrombin, respectively (StatPearls, 2023). These receptors are primary therapeutic targets for antiplatelet agents like clopidogrel, ticagrelor, and abciximab, which are used to prevent ischemic events in patients with cardiovascular disease (PubMed, PMID: 27034445). While effective at preventing thrombosis, pharmacological inhibition of these proteins inherently increases the risk of bleeding complications, necessitating a balance between efficacy and safety (NIH, 2022). Other receptors in this group, such as P-selectin and Glycoprotein VI, are also involved in inflammation and collagen binding, expanding the therapeutic potential of this class (UniProt, 2024). The expression and function of these proteins are often used as biomarkers for platelet reactivity and to monitor the efficacy of antiplatelet therapy (Gremmel et al., 2016). Overall, these proteins are fundamental to vascular integrity and are central to the management of acute coronary syndromes and stroke.
Inhibition of ligand binding to platelet surface receptors (e.g., fibrinogen to GPIIb/IIIa), antagonism of agonist-induced signaling (e.g., ADP at P2Y12 or thrombin at PAR-1), and interference with platelet-vessel wall adhesion.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet surface receptors and adhesive proteins.